← Back

Candel Therapeutics Inc

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Price · split & dividend adjusted
News & notes moving CADL
CADL▼

Candel Therapeutics Q2 GAAP EPS misses by $0.29

Candel Therapeutics reported a second-quarter GAAP loss of $0.52 per share, missing analyst expectations by $0.29. The company held cash and cash equivalents of $201.6 million as of June 30, 2026, which it expects will fund operations into the first quarter of 2028. That runway includes activities to support the potential commercial launch of aglatimagene in 2027.
CADL ▼
Seeking Alpha·13dRead more ▾
CADL2

Candel Therapeutics Grants Inducement Stock Options to New Chief Commercial Officer

Candel Therapeutics granted inducement stock options to newly appointed Chief Commercial Officer Mark Sims. The options allow the purchase of 285,000 shares of common stock at an exercise price of $10.03 per share, matching the July 6, 2026 closing price on Nasdaq. The award vests 25% on the first anniversary of Mr. Sims' start date, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. The grant was made under the company's 2025 Inducement Plan as an employment inducement in accordance with Nasdaq Listing Rule 5635(c)(4).
CADL
GlobeNewswire·49dRead more ▾
CADL▲

Five Biotech Stocks Surge 105% to 235% to New Highs

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.
BDSX ▲CADL ▲INDV ▲MIRM ▲TWST ▲
RTTNews·58dRead more ▾
CADL▲

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. He will lead commercial strategy and launch readiness for the Biologics License Application submission planned for the fourth quarter of 2026 and the estimated 2027 launch of aglatimagene besadenovec, the company's localized prostate cancer treatment. Sims previously served at AstraZeneca as Vice President and Global Franchise Head, directing commercial strategy for one of its largest business franchises. President and CEO Paul Peter Tak noted that intermediate- to high-risk localized prostate cancer represents a large market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment. Sims brings over 25 years of experience from roles at AstraZeneca, Novartis Idenix Pharmaceuticals, and Merck & Co.
CADL ▲
ExecEdge·62dRead more ▾
© 2026 MarketDXAsset